Methylxanthine therapy for apnea of prematurity: Evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial

Biology of the Neonate

Volumn 88, Issue 3, 2005, Pages 208-213

  Schmidt, Barbara ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Apnea of prematurity; Caffeine; Controlled clinical trial; Disability; Methylxanthine; Very low birth weight infant

Indexed keywords

CAFFEINE; METHYLXANTHINE;

APNEA; BEHAVIOR DISORDER; BLINDNESS; BRAIN INJURY; BRAIN ISCHEMIA; CEREBRAL PALSY; CHILD GROWTH; COGNITIVE DEFECT; DEATH; DISABILITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; GROWTH DISORDER; HEARING IMPAIRMENT; HUMAN; LONG TERM CARE; NEUROMUSCULAR DISEASE; NEUROMUSCULAR FUNCTION; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK; SURVIVAL; TREATMENT OUTCOME;

AGING; APNEA; BLINDNESS; CEREBRAL PALSY; COGNITION DISORDERS; DEAFNESS; FOLLOW-UP STUDIES; HUMANS; INFANT MORTALITY; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; TREATMENT OUTCOME; XANTHINES;

EID: 26444537383     PISSN: 00063126     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087584     Document Type: Review

References (57)

1. Allen MC: Preterm outcomes research: a critical component of neonatal intensive care. Ment Retard Dev Disabil Res Rev 2002;8:221-233.
2. Doyle LW: Victorian Infant Collaborative Study Group. Outcome at 5 years of age of children 23 to 27 weeks' gestation: refining the prognosis. Pediatrics 2001;108:134-141.
3. Marlow N, Wolke D, Bracewell MA, Samara M, EPICure Study Group: Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005;352:9-19.
4. Bhutta AT, Cleves MA, Casey PH, Cradock MM, Anand KJ: Cognitive and behavioral outcomes of school-aged children who were born preterm: a meta-analysis. JAMA 2002;288:728-737.
5. Whitfield MF, Grunau RV, Holsti L: Extremely premature (< or = 800 g) schoolchildren: multiple areas of hidden disability. Arch Dis Child Fetal Neonatal Ed 1997;77:F85-F90.
6. Anderson P, Doyle LW: Victorian Infant Collaborative Study Group. Neurobehavioral outcomes of school-age children born extremely low birth weight or very preterm in the 1990s. JAMA 2003;289:3264-3272.
7. Emsley HC, Wardle SP, Sims DG, Chiswick ML, D'Souza SW: Increased survival and deteriorating developmental outcome in 23- to 25-week-old gestation infants, 1990-94 compared with 1984-89. Arch Dis Child Fetal Neonatal Ed 1998;78:F99-F104.
8. Wilson-Costello D, Friedman H, Minich N, Fanaroff AA, Hack M: Improved survival rates with increased neurodevelopmental disability for extremely low birth weight infants in the 1990s. Pediatrics 2005;115:997-1003.
9. Ambalavanan N, Whyte RK: The mismatch between evidence and practice. Common therapies in search of evidence. Clin Perinatol 2003;30:305-331.
10. Schmidt B: Methylxanthine therapy in premature infants: sound practice, disaster, or fruit-less byway? J Pediatr 1999;135:526-528.
11. Sinclair JC, Haughton DE, Bracken MB, Horbar JD, Soll RF: Cochrane neonatal systematic reviews: a survey of the evidence for neonatal therapies. Clin Perinatol 2003;30:285-304.
12. Kuzemko JA, Paala J: Apnoeic attacks in the newborn treated with aminophylline. Arch Dis Child 1973;48:404-406.
13. 2: treatment with caffeine, 19-year follow-up. Birth Defects Orig Artic Ser 1979;15:437-445.
14. Conroy S, McIntyre J, Choonara I: Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999;80:F142-F145.
15. O'Donnell CP, Stone RJ, Morley CJ: Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 2002; 110(e52). URL: http://www.pediatrics.org/cgi/content/full/110/5/e52
16. 't Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN: A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics 2001;108:1089-1093.
17. Henderson-Smart DJ, Steer P: Methylxanthine treatment for apnea in preterm infants. Cochrane Database Syst Rev 2001;3:CD000140.
18. Pesce AJ, Rashkin M, Kotagal U: Standards of laboratory practice: theophylline and caffeine monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998;44:1124-1128.
19. Erenberg A, Leff RD, Hack DG, Mosdell KW, Hicks GM, Wynne BA: Caffeine citrate for the treatment of apnea of prematurity: a double-blind placebo-controlled study. Pharmacotherapy 2000;20:644-652.
20. Fredholm BB: Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol 1995;76:93-101.
21. Millar D, Schmidt B: Controversies surrounding xanthine therapy. Semin Neonatol 2004;9:239-244.
22. Gerhardt T, McCarthy J, Bancalari E: Effect of aminophylline on respiratory center activity and metabolic rate in premature infants with idiopathic apnea. Pediatrics 1979;63:537-542.
23. Milsap RL, Krauss AN, Auld PAM: Oxygen consumption in apneic premature infants after low-dose theophylline. Clin Pharmacol Ther 1980;28:536-540.
24. Carnielli VP, Verlato G, Benini F, et al: Metabolic and respiratory effects of theophylline in the preterm infant. Arch Dis Child Fetal Neonatal Ed 2000;83:F39-F43.
25. Bauer J, Maier K, Linderkamp O, Hentschel R: Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics 2001;107:660-663.
26. Dunwiddie TV, Masino SA: The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001;24:31-55.
27. Etzel BA, Guillet R: Effects of neonatal exposure to caffeine on adenosine A1 receptor ontogeny using autoradiography. Dev Brain Res 1994;82:223-230.
28. Deckert J: The adenosine A(2A) receptor knockout mouse: a model for anxiety? Int J Neuropsychopharmcol 1998;1:187-190.
29. Gimenez-Llort L, Fernandez-Teruel A, Escorihuela RM, et al: Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur J Neurosci 2002;16:547-550.
30. Johansson B, Halldner L, Dunwiddie TV, et al: Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA 2001;98:9407-9412.
31. Ledent C, Vaugeois JM, Schiffmann SN, et al: Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature 1997;388:674-678.
32. Kuzemko JA: Use of methylxanthines in the management of apneic attacks in the newborn. Neoreviews 2003;4:e62-e63.
33. Bayley N: Bayley Scales of Infant Development: Manual, ed 2. San Antonio, The Psychological Corp-Harcourt Brace, 1993.
34. Aylward GP: Cognitive and neuropsychological outcomes: more than IQ scores. Ment Retard Dev Disabil Res Rev 2002;8:234-240.
35. Aylward GP: Cognitive function in preterm infants. JAMA 2003;289:752-753.
36. Goyen TA, Lui K: Longitudinal motor development of 'apparently normal' high-risk infants at 18 months, 3 and 5 years. Early Hum Dev 2002;70:103-115.
37. Sattler JM: Assessment of Children: Behavioral and Clinical Applications, ed 4. La Mesa, Sattler, 2002.
38. Bennett CC, Johnson A, Field DJ, Elbourne D, for the UK Collaborative ECMO Trial Group: UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation: follow-up to age 4 years. Lancet 2001;357:1094-1096.
39. De Kleine MJ, den Ouden AL, Kollee LA, et al: Development and evaluation of a follow-up assessment of preterm infants at 5 years of age. Arch Dis Child 2003;88:870-875.
40. Palisano R, Rosenbaum P, Walter S, et al: Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997;30:214-223.
41. Bracewell M, Marlow N: Patterns of motor disability in very preterm children. Ment Retard Dev Disabil Res Rev 2002;8:241-248.
42. Beery KE, Buktenica NA, Beery NA: The Beery-Buktenica Developmental Test of Visual-Motor Integration, ed 5 (VMI). Parsippany, Modern Curriculum Press, 2004.
43. Henderson SE, Sugden DA: Movement Assessment Battery for Children (Movement ABC). San Antonio, The Psychological Corp-Harcourt Brace, 1992.
44. Cooke RWI, Foulder-Hughes L: Growth impairment in the very preterm and cognitive and motor performance at 7 years. Arch Dis Child 2003;88:482-487.
45. Foulder-Hughes LA, Cooke RWI: Motor, cognitive, and behavioral disorders in children born very preterm. Dev Med Child Neurol 2003;45:97-103.
46. Jongmans M, Mercuri E, de Vries L, Dubowitz L, Henderson SE: Minor neurological signs and perceptual-motor difficulties in prematurely born children. Arch Dis Child Fetal Neonatal Ed 1997;76:F9-F14.
47. Achenbach TM: Manual for the Child Behavior Checklist/1.5-5. Burlington, University of Vermont/Department of Psychiatry, 2002.
48. Hille ETM, den Ouden AL, Saigal S, et al: Behavioural problems in children who weigh 1,000 g or less at birth in four countries. Lancet 2001;357:1641-1643.
49. Kroes M, Kalff AC, Steyaert J, et al: A longitudinal community study: Do psychosocial risk factors and Child Behavior Checklist scores at 5 years of age predict psychiatric diagnoses at a later age? J Am Acad Child Adolesc Psychiatry 2002;41:955-963.
50. MacGregor R, Evans D, Sugden D, Gaussen T, Levene M: Outcome at 5-6 years of prematurely born children who received morphine as neonates. Arch Dis Child Fetal Neonatal Ed 1998;79:F40-F43.
51. Nadeau L, Boivin M, Tessier R, Lefebvre F, Robaey P: Mediators of behavioral problems in 7-year-old children born after 24-28 weeks of gestation. J Dev Behav Pediatr 2001;22:1-10.
52. Bohm B, Katz-Salamon M, Smedler AC, Lagercrantz H, Forssberg H: Developmental risks and protective factors for influencing cognitive outcome at 5 1/2 years of age in very-low birth-weight children. Dev Med Child Neurol 2002;44:508-516.
53. Espy KA, Stalets MM, McDiarmid MM, et al: Executive functions in preschool children born preterm: application of cognitive neuroscience paradigms. Neuropsychol Dev Cogn Sect C Child Neuropsychol 2002;8:83-92.
54. Anderson PJ, Doyle LW, Victorian Infant Collaborative Study Group: Executive functioning in school-aged children who were born very preterm or with extremely low birth weight in the 1990s. Pediatrics 2004;114:50-57.
55. Anderson P: Assessment and development of executive function during childhood. Neuropsychol Dev Cogn C Child Neuropsychol 2002;8:71-82.
56. Gioia GA, Espy KA, Isquith P: Behavior Rating Inventory of Executive Function (BRIEF-P). Odessa/Fla, Psychological Assessment Resources, 2003.
57. Wechsler Preschool and Primary Scale of Intelligence, ed 3 (WPPSI-III) Manual. Toronto, The Psychological Corp-Harcourt Canada, 2002.